Myant Acquires mmHg to Enhance Cardiac Precision Medicine

Myant Corp., a leader in precision medicine for chronic disease prevention, has announced the acquisition of mmHg Inc., a digital health company focused on remote blood pressure monitoring and cardiovascular risk management. This strategic acquisition allows Myant to expand its market reach in the U.S., leveraging mmHg’s existing customer base and partnership with A&D Medical. The acquisition is part of Myant’s broader strategy to advance personalized, AI-driven remote healthcare. mmHg’s platform enables healthcare providers to remotely monitor and analyze blood pressure and key cardiovascular indicators, aligning patient data with clinical best practices to improve decision-making precision. Esteemed institutions such as Harvard's Beth Israel Deaconess and Johns Hopkins rely on this platform to enhance patient outcomes and clinical research. By integrating mmHg’s technology with Myant’s textile computing and advanced material capabilities, healthcare providers can access continuous real-time patient data, leading to earlier disease detection, personalized treatment plans, and improved chronic disease management. The acquisition underscores Myant's commitment to leveraging AI and advanced materials to improve patient outcomes, particularly as the company experiences significant growth, including expansion into the EU and leadership enhancement with the hiring of AI expert Dr. Xin Gao.